See what Medtronic, Abbott, and Monteris Medical were up to this time last year.

Katie Hobbins, Managing Editor

June 1, 2023

1 Min Read
Calendar pages
Archive Holdings Inc. / The Image Bank via Getty Images

Medtech Hot Takes of May

These were among the most thought-provoking quotes we heard from medical device and diagnostics professionals in May.

CooperVision Eyes Specialty Lens Growth in Nordic Region

The company acquired EnsEyes to accelerate the growth of specialty lens adoption across the Nordic markets.

Manufacturer of Balloon Catheters Expands into Ireland

Biomerics said the new Balloons & Balloons Catheters Centre of Excellence in Galway, Ireland represents its first facility in Europe, and the second facility outside the United States after Costa Rica.

FDA Approves Medtronic's In.Pact 018 DCB in Wake of Recalls

The In.Pact 018 drug-coated balloon (DCB) catheter was built on the same platform technology as the In.Pact Admiral DCB, some of which were recently recalled due to manufacturing issues. The In.Pact 018 has not been evaluated in a clinical study.

Abbott Scores a Big Win in Diabetes

FDA cleared Abbott's FreeStyle Libre 3, which is expected to be the most accurate and smallest continuous glucose monitoring sensor on the market.

MedNet Launches New Tuohy-Borst Adapters and More Supplier News

Here's what was new in the world of medical device suppliers during the week of May 29.

A New Gentler Way to Get an IUD?

This suction-based cervical device has been shown to reduce pain and bleeding during intrauterine device (IUD) procedures.

This Surgical Alternative for Recurrent Brain Tumors Is LITT

Post-market data shows laser interstitial thermal therapy (LITT) using Monteris Medical's NeuroBlate System offers an effective alternative to traditional surgery for patients with newly diagnosed and recurrent glioblastoma, a fast-growing and aggressive type of brain tumor.

Can Imaging Data Increase Success Rates of Cancer Trials?

Median Technologies' new Imaging Lab will provide biopharmaceutical companies with decision-making tools for cancer trials by leveraging images with data mining and artificial intelligence.

About the Author(s)

Katie Hobbins

Managing Editor, MD+DI

Katie Hobbins is managing editor for MD+DI and joined the team in July 2022. She boasts multiple previous editorial roles in print and multimedia medical journalism, including dermatology, medical aesthetics, and pediatric medicine. She graduated from Cleveland State University in 2018 with a bachelor's degree in journalism and promotional communications. She enjoys yoga, hand embroidery, and anything DIY. You can reach her at [email protected].

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like